瑞舒伐他汀治疗老年冠心病合并高脂血症的机制研究  

Mechanisms of rosuvastatin in treatment of elderly patients with coronary heart disease complicating hyperlipidemia

作　　者：黄涛[1] 曾恋[1] 田井强 冉旋[1] 冉擘力[2] 

机构地区：[1]重庆医科大学附属第一医院酉阳医院心血管内科,409800 [2]重庆市第三人民医院心血管内科,400014

出　　处：《重庆医学》2016年第20期2801-2803,共3页Chongqing medicine

摘　　要：目的观察老年冠心病合并高脂血症患者给予瑞舒伐他汀治疗后,血清中血脂、超敏C-反应蛋白(hs-CRP)、乳脂肪球表皮生长因子8(MFG-E8)及Klotho基因水平的变化,以探讨瑞舒伐他汀治疗老年冠心病患者高脂血症的作用机制及应用价值。方法将酉阳医院接受治疗的129例冠心病合并高脂血症老年患者分为两组,对照组仅接受常规治疗,观察组在常规治疗基础上给予每日10mg瑞舒伐他汀治疗。以3个月为治疗周期,比较两组间以及同组治疗前后血脂、hs-CRP、MFG-E8及Klotho水平差异。结果两组患者治疗前血脂、hs-CRP、MFG-E8及Klotho水平均无明显差异。与对照组相比,观察组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)水平显著下降,而HDL-C水平显著升高,差异具有统计学意义(P<0.05)。此外,观察组hs-CRP水平显著低于对照组(P<0.05),观察组血清MFG-E8及Klotho水平较对照组升高,两组间差异具有统计学意义(P<0.05)。结论瑞舒伐他汀可降低血脂和hs-CRP水平,上调MFG-E8及Klotho表达水平,通过减轻炎性反应、抗血管衰老,从而有效地治疗冠心病合并高脂血症的老年患者。Objective To observe the changes of serum lipids,hs-CRP,MFG-E8 and Klotho gene levels after rosuvatatin treatment in elderly patients with coronary heart disease complicating hyperlipidemia for investigating the action mechanisms of rosuvatatin and its application value. Methods Totally 129 elderly patients with coronary artery disease complicating hyperlipidemia in our hospital were randomly divided into two groups. The control group received only conventional treatment, while on this basis the rosuvatatin group was given rosuvastatin 10 mg everyday, with 2 months as a treatment cycle. Blood lipids, hs-CRP, MFG-E8 and Klotho gene levels before and after treatment were compared between the two groups. The regulation effect of rosuvatatin was investigated Results The blood lipod, hs-CRP, MFG-E8 and Klothc before treatment had no obvious difference between the two groups. The levels of TC,LDL-C and TG after treatment m the rosuvatatin group were significantly decreased compared with the control group,while the HDL-C level was significantly increased, the differences were statistically significant（P〈0.05）. In addition,the hs-CRP level after treatment in the rosuvatatin group was significantly lower than that in the control group（P〈0.05）. Compared with the control group, the levels of MFG-E8 and Klotho Mter treatment in the rosuvatatin group were increased, the difference was statistically significant （P〈0.05）. Conclusion Rosuvastatin could decrease the blood lipid and hs-CRP levels, upregulates the MFG-E8 and Klotho levels, alleviates the inflammatory reaction and has the anti-vascular aging effect, thus effectively treats the patients with coronary heart disease complicating hyperlipidemia.

关 键 词：冠心病 高脂血症 瑞舒伐他汀 炎性反应 抗衰老 

分 类 号：R541.4[医药卫生—心血管疾病]